This article was originally published on PharmaTimes http://www.pharmatimes.com/news/kymriah_leads_latest_round_of_smc_decisions_1301283

MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.

Related Posts